Anti-angiogenic therapy for advanced primary pulmonary lymphoepithelioma-like carcinoma: a retrospective multicenter study

Hejing Bao1,2 · Ling Zhen Ma1 · Chengzhu Zhao1 · Mengge Yu1 · Baishen Zhang4 · Juan Zhang5 · Guibao Peng6 · Xiaotong Lin7 · Yinhua Fang3 · Hehong Bao2 · Shudong Ma1

Received: 23 November 2021 / Accepted: 24 January 2022 / Published online: 4 April 2022
© The Author(s) 2022

Abstract
Purpose Primary pulmonary lympho-epithelioma-like carcinoma (PPLELC) is a rare subtype of primary non-small cell lung cancer (NSCLC). Currently, there is still lack of research data on anti-angiogenic therapy of advanced PPLELC. The purpose of this study was to investigate the efficacy and safety of anti-angiogenic therapy combined with chemotherapy compared with traditional chemotherapy for these patients.

Methods Advanced PPLELC patients admitted to six grade A hospitals from January 2013 to January 2021 were selected. The patients received anti-angiogenic therapy combined with chemotherapy (AT group) or chemotherapy (CT group) alone.

Results A total of 65 patients were included in this study, including 31 patients in the AT group treated with anti-angiogenic therapy combined with chemotherapy and 34 patients in the CT group treated with chemotherapy alone. As of October 1, 2021, the median progression-free survival (PFS) in the AT group was 11.2 months [95% confidence interval (CI), 5.9–16.5]. The median PFS in the CT group was 7.0 months [95%CI, 5.1–8.9] [Hazard Ratio (HR), 0.49; 95%CI, 0.29–0.83; \(P = 0.008\)]. The 1-year PFS rates were 41.9% and 17.6%, respectively. The overall response rates (ORR) of two groups were 45.2% (95% CI, 0.27–0.64), 38.2% (95% CI, 0.21–0.56), \(P = 0.571\). The disease control rates (DCR) of two groups were 93.5% (95% CI, 0.84–1.03), 88.2% (95% CI, 0.77–1.00), \(P = 0.756\).

Conclusion Among patients with advanced PPLELC, the PFS of patients with anti-angiogenic therapy combined with chemotherapy is better than that of patients with chemotherapy alone. Anti-angiogenic therapy combined with chemotherapy is an optional treatment scheme.

Keywords PPLELC · Anti-angiogenic therapy · Efficacy and safety · Retrospective study
Introduction

Lympho-epitheliomatoid carcinoma is a rare epithelial neoplasm originating mostly in the nasopharynx and also in the foregut (Ambrosio et al. 2011; Anand et al. 2018). Primary pulmonary lympho-epithelioma-like carcinoma is a rare subtype of primary non-small cell lung cancer that histologically resembles undifferentiated nasopharyngeal carcinoma (NPC) (Hayashi et al. 2012), the incidence in all cases of non-small cell lung cancer is about 0.7% (Anand et al. 2018; Xie et al. 2020). It was previously classified as a variant of large cell carcinoma (Travis et al. 2006), then reclassified as other and unclassified cancers in the 2015 World Health Organization (WHO) Classification of Tumors of the Lung (Travis et al. 2015).

First described by Bégin et al. (1987), PPLELC has been considered to be closely associated with Epstein–Barr virus (EBV) infection (Han et al. 2000). About 1600 cases have been reported worldwide in the past 33 years since the discovery (Kim et al. 2016; Darrason et al. 2019; Hong et al. 2019; Wu et al. 2020; Chen et al. 2021), mainly focused on the past five years, reporting mainly in Asia, especially Hong Kong, Taiwan, Guangdong and other regions. PPLELC usually affects never-smokers, is gender-neutral, and is younger than non-small cell lung cancer (Lin et al. 2016). Similar to other types of lung cancer, the prognosis is good for most patients diagnosed early with lung lympho-epithelioid, with a median overall survival of approximately 107 months and a 5-year survival of approximately 60%, compared with a mean survival of 13 months for patients with non-lung lympho-epithelioid (He et al. 2015; Liang et al. 2012).

The main treatment strategy for early PPLELC is surgery (Lin et al. 2016; Ho et al. 2006). For patients with distant metastasis, surgical treatment is not possible, and a variety of treatment modes are usually accepted, including chemotherapy, radiotherapy and immunotherapy (Kumar et al. 2017; Narayanan et al. 2019; Zhou et al. 2019; Tang et al. 2020; Qiu et al. 2019). Several treatments have been reported in the literature, but the treatment of PPLELC is empirical due to its rarity. However, there is still a lack of research data on anti-angiogenic therapy in advanced PPLELC. Therefore, this study aims to investigate the effect of anti-angiogenic therapy on advanced PPLELC patients.

Materials and methods

Patients

Patients aged 18 years or older, stage IIIB-IV, diagnosed as lung lympho-epithelioid carcinoma according to the 2015 WHO histological classification criteria for lung tumors, and without allergenic EGFR or ALK mutations; According to the Solid Tumor Response Assessment Criteria (RECIST), version 1.1 has at least one measurable lesion. This retrospective study collected data of PPLELC patients from Nanfang Hospital affiliated to Southern Medical University, Zhujiang Hospital affiliated to Southern Medical University, The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, Cancer Hospital of Sun Yat-sen University, Cancer Hospital affiliated to Guangzhou Medical University, Three Gorges Hospital affiliated to Chongqing University from January 2013 to January 2021. 65 patients with advanced PPLELC were eventually included in the study (Fig. 1).

Experimental design and treatment

In this real-world retrospective study, patients were divided into AT group treated with anti-angiogenic therapy combined with chemotherapy and CT group treated with chemotherapy. AT group received anti-angiogenic therapy, including bevacizumab (n = 22), endu (n = 6) or anlotinib (n = 3), the chemotherapy regimen included paclitaxel (n = 14), pemetrexed (n = 10) or gemcitabine (n = 7) combined with platinum or mono-therapy. The chemotherapy regimen in CT group included paclitaxel (n = 19), pemetrexed...
(n = 10) or gemcitabine (n = 5) combined with platinum or mono-therapy.

**Assessment**

The tumor response assessment program is conducted every two to four cycles. Tumor response was assessed as complete response (CR), partial response (PR), disease stability (SD), or disease progression (PD) according to RECIST version 1.1. Adverse events and laboratory abnormalities were graded according to the National Cancer Institute Standard for Common Terminology for Adverse Events, Version 4.0.

**Statistical analysis**

Efficacy was assessed in the enrolled population and safety was assessed in the treated population. Kaplan–Meier methods were used to estimate progression-free survival. T test was used for measurement data (age) and Chi-square test (Cartesian test) was used for counting data. Univariate Cox regression was used to screen individual risk factors. The independent prognostic covariate of PPLELC patients was determined by multivariate Cox regression model and forward procedure. Cox proportional risk regression was used for univariate and multivariate survival analyses. All statistical analyses were performed in IBM SPSS Statistics (Version 19.0, Armonk, NY, USA). When P value was less than 0.05, the difference was considered statistically significant.

**Results**

**Patient characteristics**

The median age of patients was 54 years (interquartile range, 48–62 years). There were 38 female patients (58.5%) and 27 male patients (41.5%). ECOG score was 0 in 24 patients (36.9%) and 1 in 41 patients (63.1%). 18 patients (27.7%) were smokers, and 10 patients (15.4%) had a family history. There were 10 patients (15.4%) in stage IIIB and 55 patients (84.6%) in stage IV. Patients with single organ metastasis accounted for 19 (29.2%), and patients with multiple organ metastasis accounted for 46 (70.8%). The most common tumor sites were middle lobe of right lung and lower lobe of right lung, with 18 (27.7%) and 17 (26.1%) patients, respectively. There were 61 patients (95.3%) who were positive for Epstein–Barr virus, 15 patients (23.1%) had received radiotherapy, and 4 patients (6.2%) with gene mutations, including 3 gene mutations in the AT group, which were NRAS Q61L (14.5%) missense mutation, SMAD4 K110Ter (19.5%) mutation and FGFR3–TACC3 (F17:T10) fusion. MYC amplification was found in 1 case in CT group. There was no significant difference between the two groups at baseline (P > 0.05). (Table 1).

**Efficacy**

The minimum follow-up time was about 1.4 months. Median follow-up time was 18 months in the AT group (95% CI, 13.5–26) and 19 months in the CT group (95% CI, 13–28). AT the end of the follow-up period, 11 patients (35.5%) in the AT group and 12 patients (35.3%) in the CT group continued treatment. Anti-angiogenic therapy was administered either as up-front or salvage therapy (first-line n = 18, ≥ second-line n = 13, cross-line n = 7), while chemotherapy was used in the first-line therapy.

There were no CR cases in both AT group and CT group. In AT group, 14 patients (45.2%) reached PR, 15 patients (48.3%) reached SD, and 2 patients (6.5%) did not respond to treatment. In CT group, 13 patients (38.2%) reached PR, 17 patients (50.0%) reached SD, and 4 patients (11.8%) did not respond to treatment. The ORR of AT group and CT group were 14 (45.2%, 0.27–0.64) and 13 (38.2%, 0.21–0.56), P = 0.571; DCR were 29 (93.5%, 0.84–1.03) and 30 (88.2%, 0.77–1.00), P = 0.756 (Table 2, Fig. 2).

The median PFS was 11.2 months in the AT group [95% CI, 5.9–16.5] and 7.0 months in the CT Group [95% CI, 5.1–8.9] [HR, 0.49; 95% CI, 0.29–0.83; P = 0.008]. The 1-year PFS rates were 41.9% and 17.6%, respectively (Fig. 3, Supplement Table 1).

In this study, we reported a 59-year-old female patient with FGFR3–TACC3 (F17:T10) fusion, no smoking history, tumor located in the right lung with lymphatic, liver, and bone metastases, clinical stage T4N3M1, pathologically confirmed as PPLELC, Genetic analysis revealed FGFR3–TACC3 (F17:T10) fusion without EGFR, ALK and other conventional mutations. The patient was treated with anlotinib in combination with albumin–paclitaxel and carboplatin at the physician’s recommendation, achieving disease control and PFS for 8 months (Fig. 4).

**Safety**

Treatment-related adverse events (both hematological and non-hematological poisoning events) occurred more frequently in the AT group than in the CT group. In the AT group, there were 17 cases (54.8%) of grade 3 and 8 cases (25.8%) of grade 4 treatment-related adverse events. There were 13 cases (38.2%) of grade 3 and 12 cases (35.3%) of grade 4 treatment-related adverse reactions in the CT group. The most common adverse reactions in AT group were decreased appetite 7 (22.6%), anemia 8 (25.8%), leukopenia 14 (45.2%), neutropenia 16 (51.6%), and decreased platelet 8 (25.8%). Anemia 10 (29.4%), leukopenia 14 (41.2%),
neutropenia 15 (44.1%), and thrombocytopenia 10 (29.4%) were most common in the CT group (Table 3).

**Discussion**

PPLELC is a rare subtype of NSCLC. In this era of targeted therapy and checkpoint inhibitors for non-small cell lung cancer, anti-angiogenic drugs still play an important role (Shukla et al. 2020). However, the prognosis of advanced PPLELC is poor, due to the lack of drug treatment data, the role of anti-angiogenic therapy in PPLELC is unknown. It is worth exploring the effect of anti-angiogenic therapy in PPLELC.

Induction of angiogenesis is one of the 10 characteristics of malignant tumors. Angiogenesis provides essential nutrients for tumor growth and is an important prerequisite for tumor hematogenous dissemination. The ECOG-4599 study established the status of bevacizumab combined with first-line chemotherapy (Sandler et al. 2007). Small molecule

---

Table 1  Baseline characteristics

|                      | All patients (n = 65) | AT group (n = 31) | CT group (n = 34) | P  |
|----------------------|-----------------------|------------------|-------------------|----|
| Age, years Median(IQR) | 54 (48–62)           | 55 (48.5–61.5)   | 54 (48–61.25)     | 0.892 |
| Sex                  |                       |                  |                   | 0.285 |
| Female               | 27 (41.5%)            | 15 (48.4%)       | 12 (35.3%)        |     |
| Male                 | 38 (58.5%)            | 16 (51.6%)       | 22 (64.7%)        |     |
| ECOG performance status |                     |                  |                   | 0.592 |
| 0                    | 24 (36.9%)            | 12 (38.7%)       | 11 (32.3%)        |     |
| 1                    | 41 (63.1%)            | 19 (61.3%)       | 23 (67.6%)        |     |
| Smokers              | 18 (27.7%)            | 10 (32.3%)       | 8 (23.5%)         | 0.432 |
| Family history       | 10 (15.4%)            | 3 (9.7%)         | 7 (20.6%)         | 0.309 |
| TNM                  |                       |                  |                   | 0.382 |
| III B                | 10 (15.4%)            | 3 (9.7%)         | 7 (20.6%)         |     |
| IV                   | 55 (84.6%)            | 28 (90.3%)       | 27 (79.4%)        |     |
| Metastases           |                       |                  |                   | 0.260 |
| Single organ         | 19 (29.2%)            | 7 (22.6%)        | 12 (35.3%)        |     |
| Multiple organ       | 46 (70.8%)            | 24 (77.4%)       | 22 (64.7%)        |     |
| Tumor location       |                       |                  |                   | 0.903 |
| Left upper lobe of lung | 10 (15.4%)          | 5 (16.1%)        | 5 (14.7%)         |     |
| Left lower lobe of lung | 15 (23.1%)          | 8 (25.8%)        | 7 (20.6%)         |     |
| Right upper lobe of lung | 5 (7.7%)            | 2 (6.5%)         | 3 (8.8%)          |     |
| Right middle lobe of lung | 18 (27.7%)        | 7 (22.6%)        | 11 (32.4%)        |     |
| Right lower lobe of lung | 17 (26.1%)          | 9 (29.0%)        | 8 (23.5%)         |     |
| EB(+)                | 61 (95.3%)            | 29 (93.5%)       | 32 (94.1%)        | 1.0  |
| Radiotherapy         | 15 (23.1%)            | 6 (19.3%)        | 9 (26.5%)         | 0.496 |
| Gene mutation        | 4 (6.2%)              | 3 (9.7%)         | 1 (2.9%)          | 0.540 |

Data are median number (IQR) or n (%). *IQR* interquartile range. Data from all patients who were enrolled in this study

Table 2  Efficacy of treatments

|                      | AT group (n = 31) | CT group (n = 34) | P  |
|----------------------|------------------|------------------|----|
| Best overall response |                  |                  | 0.763 |
| Complete response    | 0                | 0                |     |
| Partial response     | 14 (45.2%)       | 13 (38.2%)       |     |
| Stable disease       | 15 (48.3%)       | 17 (50.0%)       |     |
| Progressive disease  | 2 (6.5%)         | 4 (11.8%)        |     |
| Objective response   | 14 (45.2%, 0.27–0.64) | 13 (38.2%, 0.21–0.56) | 0.571 |
| Disease control      | 29 (93.5%, 0.84–1.03) | 30 (88.2%, 0.77–1.00) | 0.756 |

Data are n (%). Confirmed complete and partial responses were assessed by the investigator according to the Response Evaluation Criteria in Solid Tumors, version 1.1

---

(Shukla et al. 2020)
Tyrosine kinase inhibitor (TKI) drugs targeting angiogenesis have become one of the research hotspots in recent years. The biggest feature of small molecule drugs is that their target coverage is more comprehensive. In addition to VEGF/R and other pathways, they can also cover PDGF/R, FGF/FGFR and other pathways.

In this study, a patient with FGFR3–TACC3 fusion was reported. In general, operable FGFR3 gene fusion is found relatively commonly in glioma and bladder cancer (Wu et al. 2013), FGFR3–TACC3 fusion has been reported in 2.5% of NPC (Yuan et al. 2014). However, FGFR3 alteration was rarely observed in NSCLC, and was detected in 0.1% of adenocarcinomas and 0.6% of squamous cell carcinomas, respectively (AACR Project GENIE Consortium 2017; Qin et al. 2019). The prevalence of FGFR3 in LELC was 4% (Chau et al. 2016). FGFR3–TACC3 is reported to be a relapsing drug resistance mechanism that can bypass EGFR blockade by all generations of EGFR TKI in NSCLC (Ou et al. 2017). In this study, FGFR3–TACC3 fusion patients respond to treatment. In the CT group, 17 patients achieved SD status, 13 patients achieved PR status, and 4 patients did not respond to treatment.

However, anti-angiogenic therapy alone does not significantly improve patient outcomes, as the removal of blood vessels transforms tumor cells into a hypoxic-tolerant phenotype. Combination of anti-angiogenic therapy with other therapies, including chemotherapy, radiotherapy, immunotherapy and anti-EGFR therapy, has good efficacy due to the vaso-normalization effect induced by anti-angiogenic agents (Tian et al. 2020). Radiation alone as the sole means of treating cancer often triggers the angiogenesis pathway, leading to upregulation of multiple angiogenic growth factors, and anti-angiogenic inhibitors can help overcome this fact (Rani and Prabhu 2021). Randomized Phase III studies have also shown that treatment with antiangiogenic agents in combination with programmed cell death ligand 1 (PD-L1) antibodies significantly improves survival compared with standard therapy in renal cell carcinoma (RCC), NSCLC and hepatocellular carcinoma (HCC) (Hack et al. 2020). However, there are still many problems to be solved, such as how to choose a more reasonable combination partner for anti-angiogenic therapy, the timing, recommended dosage and the proportion of anti-angiogenic inhibitor combination therapy (Tian et al. 2020). In this study, anti-angiogenic therapy combined with chemotherapy in patients with advanced PPLELC was included. The results showed that compared with chemotherapy alone, it can improve the short-term efficacy of patients.
Fig. 4 Radiographic images of the patient with FGFR3–TACC3 (F17:T10) fusion. A, B Fiber-bronchoscopy results in October 2018 indicated the growth of new organisms in the right main bronchus; C HE × 400 times, the results showed that some tumor cells were arranged in nests, with abundant cytoplasm, red staining, obvious nuclear atypia, interstitial fibrous hyperplasia accompanied by a large number of lymphocytes. D Immuno-histochemical × 400 times: PD-L1(22C3) CPS = 80; E–H Enhanced chest computed tomography images in October 2018, mass soft tissue density shadow near hilum in the upper lobe of right lung, with obstructive pneumonia, multiple lymph node metastases in mediastinum and bilateral hilum, and double lung metastases (E and G are pulmonary window, F and H are mediastinal window); I–L Enhanced chest computed tomography images in February 2019 showed that the mass soft tissue density shadow near hilum in the upper lobe of right lung was smaller than before, obstructive pneumonia was better than before, multiple lymph node metastases in mediastinum and bilateral hilum were smaller than before, and double lung metastases were smaller than before (I and K are lung window, J and L are mediastinal window); M–P Enhanced chest computed tomography images in June 2019 showed that the mass soft tissue density shadow near hilum in the upper lobe of the right lung was smaller than before, obstructive pneumonia was better than before, multiple lymph node metastases in mediastinum and bilateral hilum were smaller than before, and double lung metastases were smaller and less than before (M and O are lung window, N and P are mediastinal window)
immunotherapy and chemotherapy is a better choice, it is worth further exploration. Our study found that anti-angiogenic therapy combined with chemotherapy was more beneficial than chemotherapy alone in patients with advanced PPLELC, but there was no way to screen the dominant population, and some patients did not respond to anti-angiogenic therapy combined with chemotherapy. Both targeted therapy and immunotherapy have corresponding markers to accurately identify the population, but there is no recognized marker in the field of anti-angiogenic therapy. Bevacizumab is a monoclonal antibody with a clear target of VEGF, so it is logical that VEGF expression might predict benefit. However, clinical studies have found that VEGF expression does not predict the benefit of bevacizumab addition (Otrock et al. 2011). The tumor vasculature is a target for antiangiogenic drugs, but quantitative or qualitative measures of the vasculature cannot be used as biomarkers of efficacy because there is no standardized method for measuring micro-vessel density and there is considerable potential for selection and observer bias. The detection of vascular phenotype and tumor cell genotype is still in the stage of preclinical research (Jubb et al. 2006). Compared to using the tissue biomarkers to select effective anti-angiogenic drugs, the studies of discover and validation in the non-invasive, dynamic biomarker were at a more advanced stage, including measuring the circulating protein related to angiogenesis, circulating microRNAs, secrete body outside, circulating endothelial cells and or estimates of progenitor cells and vascular imaging (Paolo et al. 2020).

Our study has some limitations. This study was from a retrospective cohort and the number of included patients was limited. This is due to the rarity of PPLELC and the small number of patients, even fewer patients in the advanced stage of metastasis. Moreover, the emergence and application of different anti-angiogenic drugs in clinical practice will affect the results. Differences in patients’ chemotherapy regimens also affected the results. However, this study first reported the value of anti-angiogenic therapy in advanced PPLELC. Data were collected from multiple centers in this study, and patients came from areas with high PPLELC incidence, which has certain advantages.

In conclusion, compared with the current treatment of patients with advanced PPLELC, anti-angiogenic therapy is clinically beneficial and sufficiently safe, and the number of patients should be further expanded or the follow-up period extended to further observe the survival benefit.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s00432-022-03935-0.

Acknowledgements The authors are grateful to all staff at the study centre who contributed to this study.

Author contributions HJB: Conceptualization; Data curation; Resources; Writing—original draft; Writing—review & editing. LZM, XXL, MGY: Methodology; Visualization; Writing—review & editing. BSZ, IZ, GBP, XTL: Resources; Validation; Visualization. YHF,
HBB: Formal analysis; Methodology; Software; Writing—original draft. SDM: Funding acquisition; Project administration; Supervision; Visualization. All authors read and approved the final manuscript.

**Funding** This work was supported by the Antitumor Angiogenesis Targeted Therapy Research Fund of the Chinese Society of Clinical Oncology (Y-S2016-004), the Nanfang Hospital Dean’s Fund (2018B013), the Wu Jieping Medical Foundation (320.6750.19061) and the General project of Chongqing Natural Science Foundation (cstc2021jcyj-msxmX0950).

**Data availability** Datasets generated and analyzed during the study are available from HB on reasonable request.

**Code availability** Not applicable.

**Declarations**

**Conflict of interest** All authors declare no conflicts of interest associated with this manuscript.

**Ethics approval** Because of the nature of retrospective design and patient anonymization, the ethical board of the Institutional Ethics Committee of the Southern medical university Nanfang Hospital approved the retrospective study.

**Consent to participate** The need for written informed consent was waived due to the retrospective nature of the study.

**Consent for publication** All authors have consented to publication of the results presented in this manuscript.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

AAARC Project GENIE Consortium (2017) AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discov 7(8):818–831. https://doi.org/10.1158/2159-8290.CD-17-0151

Ambrosio MR, Rocca BJ, Onorati M et al (2011) Lymphoepithelioma-like carcinoma of the ovary. Int J Surg Pathol 19(4):514–517. https://doi.org/10.1177/10668969103454336

Anand A, Zayac A, Curtiss C, Graziano S (2018) Pulmonary lymphoepithelioma-like carcinoma disguised as squamous cell carcinoma. J Thorac Oncol 13(5):e75–e76. https://doi.org/10.1016/j.jtho.2017.11.133

Bégin LR, Eskandari J, Joncas J, Panasci L (1987) Epstein-Barr virus related lymphoepithelioma-like carcinoma of lung. J Surg Oncol 36(4):280–283. https://doi.org/10.1002/jso.2930360413

Chau SL, Tong JH, Chow C et al (2020) Distinct molecular landscape of Epstein-Barr virus associated pulmonary lymphoepithelioma-like carcinoma revealed by genomic sequencing. Cancers (basel) 12(8):2065. https://doi.org/10.3390/cancers12082065

Chen J, Gu C, Chen X et al (2021) Clinicopathological and prognostic analyses of 86 resected pulmonary lymphoepithelioma-like carcinomas. J Surg Oncol 123(2):544–552. https://doi.org/10.1002/jso.26276

Darrason M, Martin A, Sousman M et al (2019) Immunotherapy for LELC: case report and a focused review. Clin Lung Cancer 20(3):e393–e401. https://doi.org/10.1016/j.cllc.2018.12.008

Di Paolo V, Colletti M, Ferruzzi V et al (2020) Circulating biomarkers for tumor angiogenesis: where are we? Curr Med Chem 27(14):2361–2380. https://doi.org/10.2174/092987325666180821151409

Hack SP, Zhu AX, Wang Y (2020) Augmenting anticancer immunity through combined targeting of angiogenic and PD-1/PD-L1 pathways: challenges and opportunities. Front Immunol 11:598877. https://doi.org/10.3389/fimmu.2020.598877

Han AJ, Xiong M, Zong YS (2000) Association of Epstein-Barr virus with lymphoepithelioma-like carcinoma of the lung in southern China. Am J Clin Pathol 114(2):220–226. https://doi.org/10.1309/148K-ND54-6NJX-NA61

Hayashi T, Haba R, Tanizawa J et al (2012) Cytopathologic features and differential diagnostic considerations of primary lymphoepithelioma-like carcinoma of the lung. Diagn Cytopathol 40(9):820–825. https://doi.org/10.1002/dc.21670

He J, Shen J, Pan H, Huang J, Liaong W, He J (2015) Pulmonary lymphoepithelioma-like carcinoma: a surveillance, epidemiology, and end results database analysis. J Thorac Dis 7(12):2330–2338. https://doi.org/10.3978/j.issn.2072-1439.2015.12.62

Ho JC, Wong MP, Lam WK (2006) Lymphoepithelioma-like carcinoma of the lung. Respiriology 11(5):539–545. https://doi.org/10.1111/j.1440-1843.2006.00910.x

Hong S, Liu D, Luo S et al (2019) The genomic landscape of Epstein-Barr virus-associated pulmonary lymphoepithelioma-like carcinoma. Nat Commun 10(1):3108. https://doi.org/10.1038/s41467-019-10902-w

Jubb AM, Oates AJ, Holden S, Koeppen H (2006) Predicting benefit from anti-angiogenic agents in malignancy. Nat Rev Cancer 6(8):626–635. https://doi.org/10.1038/nrc1946

Kim C, Rajan A, DeBrito PA, Giaccone G (2016) Metastatic lymphoepithelioma-like carcinoma of the lung treated with nivolumab: a case report and focused review of literature. Transl Lung Cancer Res 5(6):720–726. https://doi.org/10.21037/tlcr.2016.11.06

Kumar V, Dave V, Harris J, Huang Y (2017) Response of advanced stage recurrent lymphoepithelioma-like carcinoma to nivolumab. Immunotherapy 9(12):955–961. https://doi.org/10.2217/imt-2017-0067

Liang Y, Wang L, Zhu Y et al (2012) Primary pulmonary lymphoepithelioma-like carcinoma: fifty-two patients with long-term follow-up. Cancer 118(19):4748–4758. https://doi.org/10.1002/cncr.274522

Lin Z, Situ D, Chang X et al (2016) Surgical treatment for primary pulmonary lymphoepithelioma-like carcinoma. Interact Cardiovasc Thorac Surg 23(1):41–46. https://doi.org/10.1093/icvts/ivw064

Narayanan A, Knollmann FD, Walby JAS, Lim S, Gandara DR, Riess JW (2019) EBV-positive primary pulmonary lymphoepithelioma-like carcinoma response to PD-L1 blockade. Clin Lung Cancer 20(3):e238–e241. https://doi.org/10.1016/j.cllc.2018.12.015

Ottrock ZK, Hatoum HA, Musallam KM, Awada AH, Shamseddine AI (2011) Is VEGF a predictive biomarker to anti-angiogenic therapy? Crit Rev Oncol Hematol 79(2):103–111. https://doi.org/10.1016/j.critrevonc.2010.07.008

Ou SI, Horn L, Cruz M et al (2017) Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR
tyrosine kinase inhibitors in EGFR mutated NSCLC patients. Lung Cancer 111:61–64. https://doi.org/10.1016/j.lungcan.2017.07.006
Qin A, Johnson A, Ross JS et al (2019) Detection of known and novel FGFR fusions in non-small cell lung cancer by comprehensive genomic profiling. J Thorac Oncol 14(1):54–62. https://doi.org/10.1016/j.jtho.2018.09.014
Qiu ZX, Zhou P, Wang K (2019) Primary pulmonary lymphoepithelioma-like carcinoma response favorably to nivolumab: a case report. Onco Targets Ther 12:8595–8600. https://doi.org/10.2147/OTT.S219512
Rani V, Prabhu A (2021) Combining angiogenesis inhibitors with radiation: advances and challenges in cancer treatment. Curr Pharm Des 27(7):919–931. https://doi.org/10.2174/1381612826666201002145454
Sandler A, Gray R, Perry MC et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer [published correction appears in N Engl J Med. 2007 Jan 18;356(3):318]. N Engl J Med 355(24):2542–2550. https://doi.org/10.1056/NEJMoa061884
Shukla NA, Yan MN, Hanna N (2020) The story of angiogenesis inhibitors in non-small-cell lung cancer: the past, present, and future. Clin Lung Cancer 21(4):308–313. https://doi.org/10.1016/j.cllc.2020.02.024
Tang Z, Fang R, Tong G, Liu P, Ou Z, Tang Y (2020) Overcoming resistance to anti-PD-1 immunotherapy in lymphoepithelioma-like carcinoma: a case report and review of the literature. Lung Cancer 146:335–340. https://doi.org/10.1016/j.lungcan.2020.06.027
Tian W, Cao C, Shu L, Wu F (2020) Anti-angiogenic therapy in the treatment of non-small cell lung cancer. Onco Targets Ther 13:12113–12129. https://doi.org/10.2147/OTT.S276150
Travis WD, Garg K, Franklin WA et al (2006) Bronchioloalveolar carcinoma and lung adenocarcinoma: the clinical importance and research relevance of the 2004 World Health Organization pathologic criteria. J Thorac Oncol 1(9 Suppl):S13–S19
Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG (2015) Introduction to the 2015 world health organization classification of tumors of the lung, pleura, thymus, and heart. J Thorac Oncol 10(9):1240–1242. https://doi.org/10.1097/JTO.0000000000000663
Wu YM, Su F, Kalyana-Sundaram S et al (2013) Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov 3(6):636–647. https://doi.org/10.1158/2159-8290.CD-13-0050
Wu Q, Wang W, Zhou P et al (2020) Primary pulmonary lymphoepithelioma-like carcinoma is characterized by high PD-L1 expression, but low tumor mutation burden. Pathol Res Pract 216(8):153043. https://doi.org/10.1016/j.prp.2020.153043
Xie Z, Liu L, Lin X et al (2020) A multicenter analysis of genomic profiles and PD-L1 expression of primary lymphoepithelioma-like carcinoma of the lung. Mod Pathol 33(4):626–638. https://doi.org/10.1038/s41379-019-0391-9
Yuan L, Liu ZH, Lin ZR, Xu LH, Zhong Q, Zeng MS (2014) Recurrent FGFR3-TACC3 fusion gene in nasopharyngeal carcinoma. Cancer Biol Ther 15(12):1613–1621. https://doi.org/10.4161/cbt.2014.961874
Zhou N, Lin Y, Peng X, Wang Y, Wang Y (2019) Thorough survey and analysis of pulmonary lymphoepithelioma-like carcinoma in Macau and multimodality treatment for advanced disease. Lung Cancer 138:116–123. https://doi.org/10.1016/j.lungcan.2019.10.004

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.